Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial?

2009 ◽  
Vol 106 (1) ◽  
pp. 49-52 ◽  
Author(s):  
Javier Del Rey ◽  
José Placer ◽  
Felip Vallmanya ◽  
Núria Pujol ◽  
Esther Prat ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bladder Cancer ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Cancer Screening Trial ◽  
Muscle Invasive ◽  
Screening Trial

Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors

Lung Cancer ◽  
2019 ◽  
Vol 138 ◽  
pp. 72-78 ◽  
Author(s):  
Donella Puliti ◽  
Mario Mascalchi ◽  
Francesca Maria Carozzi ◽  
Laura Carrozzi ◽  
Fabio Falaschi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Cardiovascular Mortality ◽  
Lung Cancer Screening ◽  
Trial Analysis ◽  
Cancer Screening Trial ◽  
Screening Trial

Second primary lung cancer in the United States: 1992–2008.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 309-309
Author(s):  
Nicholas Donin ◽  
Lorna Kwan ◽  
Andrew T. Lenis ◽  
Drakaki Alexandra ◽  
Mark S. Litwin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bladder Cancer ◽  
Cancer Screening ◽  
Cancer Survivors ◽  
Lung Cancer Screening ◽  
The United States ◽  
Second Primary ◽  
Incidence And Mortality ◽  
Screening Trial

309 Background: Tobacco smoke is a known risk factor for both bladder and lung cancer. We hypothesized that bladder cancer survivors are at high risk for second primary lung cancers (SPLC), and sought to describe the incidence and mortality attributable to SPLC among survivors of bladder cancer as well as other common cancers in the United States. Methods: We identified adult patients diagnosed with a localized primary malignancy from 8 of the most common non-pulmonary cancer sites in Surveillance, Epidemiology, and End Results (SEER) data from 1992–2008. We explored factors associated with the incidence and mortality from SPLC using bivariable and multivariable models. Finally, we compared standardized incidence rates (SIRs) for SPLC in our cohort with the control arm of the National Lung Screening Trial (NLST), a large lung cancer screening trial in patients at high risk for lung cancer. Results: We identified 1,431,809 survivors of common non-pulmonary cancers, of whom 24,477 (1.7%) developed SPLC at a mean (SD) follow-up of 5.7 (3.6) years. Bladder cancer survivors developed SPLC at twice the rate of other cancer survivors, with 10% developing SPLC in the 20 years following their bladder cancer diagnosis. Increasing age and male gender were independent risk factors for SPLC, irrespective of the primary cancer type. Of patients who developed SPLC, 19,059 (78%) died during follow-up. Lung cancer was responsible for 73% of these deaths, such that over half (57%) of the cancer survivors who develop SPLC ultimately died of lung cancer. Bladder cancer survivors demonstrated a SIR of 512 cases/100,000 person-years, which approaches the rate (572 cases/100,000 person-years) seen in the control arm of the NLST. Conclusions: Over half of patients who develop SPLC died of their disease. Almost 10% of bladder cancer survivors develop SPLC in the 20-years following their diagnosis. This rate approaches that seen in the control arm of the NLST, suggesting that the incidence in bladder cancer survivors could justify lung cancer screening in this population. Further efforts to better define the potential risks and benefits of lung cancer screening in bladder cancer survivors is warranted.

Limited contamination in the Dutch–Belgian randomized lung cancer screening trial (NELSON)

Lung Cancer ◽  
2010 ◽  
Vol 69 (1) ◽  
pp. 66-70 ◽  
Author(s):  
Eleonora Baecke ◽  
Harry J. de Koning ◽  
Suzie J. Otto ◽  
Carola A. van Iersel ◽  
Rob J. van Klaveren
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Lung Cancer Screening ◽  
Cancer Screening Trial ◽  
Screening Trial
Sign in / Sign up

Export Citation Format

Share Document